{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:05:13Z","timestamp":1790759113680,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-03006-y","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:52:04Z","timestamp":1785991924000},"page":"2925-2938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Wiktoria","family":"Pa\u0142ka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Mo\u0107ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"\u015aladowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Holko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Kawalec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"3006_CR1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S540103","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Q, Xiong Y, Shi W, Qi X (2025) Obesity and its comorbidities: current treatment options, emerging biological mechanisms, future perspectives and challenges. Diabetes Metab Syndr Obes. https:\/\/doi.org\/10.2147\/DMSO.S540103","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3006_CR2","unstructured":"World Health Organization. Obesity and overweight (2025) https:\/\/www.who.int\/obesity-and-overweight"},{"key":"3006_CR3","unstructured":"World Health Organization. WHO acceleration plan to stop obesity. WHO (2023) https:\/\/www.who.int\/WHO-acceleration-plan-to-stop-obesity. Accessed 26 Sep 2025"},{"key":"3006_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2025.100375","author":"SK Ahmed","year":"2025","unstructured":"Ahmed SK, Mohammed RA (2025) Obesity: prevalence, causes, consequences, management, preventive strategies and future research directions. Metabolism Open. https:\/\/doi.org\/10.1016\/j.metop.2025.100375","journal-title":"Metabolism Open"},{"key":"3006_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19897","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M (2023) Obesity management in adults: A review. JAMA. https:\/\/doi.org\/10.1001\/jama.2023.19897","journal-title":"JAMA"},{"key":"3006_CR6","unstructured":"European Medicines Agency. EPAR, Saxenda https:\/\/www.ema.europa.eu-EPAR\/saxenda. Accessed 26 Oct 2025"},{"key":"3006_CR7","unstructured":"Food and Drug Administration Saxenda. https:\/\/www.accessdata.fda.gov\/saxenda. Accessed 26 Oct 2025"},{"key":"3006_CR8","unstructured":"European Medicines Agency. EPAR, Wegovy https:\/\/www.ema.europa.eu-EPAR\/wegovy. Accessed 26 Oct 2025"},{"key":"3006_CR9","unstructured":"Food and Drug Administration Wegovy. https:\/\/www.accessdata.fda.gov\/wegovy. Accessed 04 Jan 2026"},{"key":"3006_CR10","unstructured":"European Medicines Agency. EPAR, Mounjaro https:\/\/www.ema.europa.eu-EPAR\/mounjaro. Accessed 26 Oct 2025"},{"key":"3006_CR11","unstructured":"Food and Drug Administration (2026) Zepbound. Accessed 16 Jan 2026 https:\/\/www.accessdata.fda.gov\/zepbound"},{"key":"3006_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","author":"QK Liu","year":"2024","unstructured":"Liu QK (2024) Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2024.1431292","journal-title":"Front Endocrinol"},{"key":"3006_CR13","unstructured":"Novo Nordisk, Novo Nordisk AS (2026) The European Commission approves more effective dose of injectable Wegovy\u00ae for adults with obesity; clinical study showed people lost about 21% of their body weight on average [Press release]. https:\/\/www.novonordisk.com"},{"key":"3006_CR14","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analysis of health care interventions: checklist and explanations. Ann Intern Med. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"3006_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3006_CR16","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al (2024) Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane. www.cochrane.org\/handbook. Accessed 11 Jan 2026"},{"key":"3006_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.01.004","author":"JP Jansen","year":"2014","unstructured":"Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R et al (2014) Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR- AMCP-NPC Good Practice Task Force report. Value Health. https:\/\/doi.org\/10.1016\/j.jval.2014.01.004","journal-title":"Value Health"},{"key":"3006_CR18","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-2-201307160-00008","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G (2013) Conceptual and technical challenges in network meta-analysis. Ann Intern Med. https:\/\/doi.org\/10.7326\/0003-4819-159-2-201307160-00008","journal-title":"Ann Intern Med"},{"key":"3006_CR19","unstructured":"Mocko P, \u015aladowska K, Holko P, Kawalec P, Pa\u0142ka W (2025) Analysis of the efficacy and safety profile of semaglutide, liraglutide and tirzepatide in the therapy of overweight and obesity: a systematic review and network meta-analysis. PROSPERO. CRD420251014401. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251014401"},{"key":"3006_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"3006_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3006_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1058","author":"G R\u00fccker","year":"2012","unstructured":"R\u00fccker G (2012) Network meta-analysis, electrical networks and graph theory. Res Synth Methods. https:\/\/doi.org\/10.1002\/jrsm.1058","journal-title":"Res Synth Methods"},{"key":"3006_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115065","author":"B Neupane","year":"2014","unstructured":"Neupane B, Richer D, Bonner AJ, Kibret T, Beyene J (2014) Network meta-analysis using R: a review of currently available automated packages. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0115065","journal-title":"PLoS ONE"},{"key":"3006_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8383","author":"SC Freeman","year":"2019","unstructured":"Freeman SC, Fisher D, White IR, Auperin A, Carpenter JR (2019) Identifying inconsistency in network meta-analysis: Is the net heat plot a reliable method? Stat Med. https:\/\/doi.org\/10.1002\/sim.8383","journal-title":"Stat Med"},{"key":"3006_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0060-8","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. https:\/\/doi.org\/10.1186\/s12874-015-0060-8","journal-title":"BMC Med Res Methodol"},{"key":"3006_CR26","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.140550","author":"N Bhatnagar","year":"2014","unstructured":"Bhatnagar N, Lakshmi PV, Jeyashree K (2014) Multiple treatment and indirect treatment comparisons: an overview of network metaanalysis. Perspect Clin Res. https:\/\/doi.org\/10.4103\/2229-3485.140550","journal-title":"Perspect Clin Res"},{"key":"3006_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2015-102088","author":"D Mavridis","year":"2015","unstructured":"Mavridis D, Giannatsi M, Cipriani A, Salanti G (2015) A primer on network meta-analysis with emphasis on mental health. Evid Based Ment Health. https:\/\/doi.org\/10.1136\/eb-2015-102088","journal-title":"Evid Based Ment Health"},{"key":"3006_CR28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1411892","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M et al (2015) A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa1411892","journal-title":"N Engl J Med"},{"key":"3006_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV et al (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2015.9676","journal-title":"JAMA"},{"key":"3006_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22726","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C et al (2020) Liraglutide 3.0\u00a0mg and Intensive Behavioral Therapy (IBT) for obesity in Primary Care: The SCALE IBT randomized controlled trial. Obes (Silver Spring). https:\/\/doi.org\/10.1002\/oby.22726","journal-title":"Obes (Silver Spring)"},{"key":"3006_CR31","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1745","author":"WT Garvey","year":"2020","unstructured":"Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A et al (2020) Efficacy and safety of liraglutide 3.0\u00a0mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: The SCALE insulin randomized controlled trial. Diabetes Care. https:\/\/doi.org\/10.2337\/dc19-1745","journal-title":"Diabetes Care"},{"key":"3006_CR32","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2032183","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2032183","journal-title":"N Engl J Med"},{"key":"3006_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L et al (2021) Semaglutide 2.4\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"key":"3006_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A et al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2021.1831","journal-title":"JAMA"},{"key":"3006_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP et al (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-022-02026-4","journal-title":"Nat Med"},{"key":"3006_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00008-0","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W et al (2022) Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(22)00008-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3006_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2403664","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, Udd\u00e9n Hemmingsson J, Hjelmes\u00e6th J, Hoffmann Morville T et al (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2403664","journal-title":"N Engl J Med"},{"key":"3006_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00182-7","author":"BM McGowan","year":"2024","unstructured":"McGowan BM, Bruun JM, Capehorn M, Pedersen SD, Pietil\u00e4inen KH, Muniraju HAK et al (2024) Efficacy and safety of once-weekly semaglutide 2.4\u00a0mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(24)00182-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3006_CR39","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2306963","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2306963","journal-title":"N Engl J Med"},{"key":"3006_CR40","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2313917","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK et al (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2313917","journal-title":"N Engl J Med"},{"key":"3006_CR41","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307563","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2307563","journal-title":"N Engl J Med"},{"key":"3006_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00226-8","author":"S Wharton","year":"2025","unstructured":"Wharton S, Freitas P, Hjelmes\u00e6th J, Kabisch M, Kandler K, Lingvay I et al (2025) Once-weekly semaglutide 7.2\u00a0mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(25)00226-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3006_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00225-6","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, Bergenheim SJ, Buse JB, Freitas P, Garvey WT, Harder-Lauridsen NM et al (2025) Once-weekly semaglutide 7.2\u00a0mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(25)00225-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3006_CR44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2502081","author":"WT Garvey","year":"2025","unstructured":"Garvey WT, Bl\u00fcher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietil\u00e4inen KH et al (2025) Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMOA2502081","journal-title":"N Engl J Med"},{"key":"3006_CR45","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206038","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2206038","journal-title":"N Engl J Med"},{"key":"3006_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D et al (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(23)01200-X","journal-title":"Lancet"},{"key":"3006_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.9217","author":"L Zhao","year":"2024","unstructured":"Zhao L, Cheng Z, Lu Y, Liu M, Chen H, Zhang M et al (2024) Tirzepatide for weight reduction in Chinese adults with obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2024.9217","journal-title":"JAMA"},{"key":"3006_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00377-2","author":"T Kadowaki","year":"2025","unstructured":"Kadowaki T, Kiyosue A, Shingaki T, Oura T, Yokote K (2025) Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(24)00377-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3006_CR49","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2410027","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V et al (2025) Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2410027","journal-title":"N Engl J Med"},{"key":"3006_CR50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R et al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 Randomized Clinical Trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA"},{"key":"3006_CR51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2416394","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E et al (2025) Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMOA2416394","journal-title":"N Engl J Med"},{"key":"3006_CR52","unstructured":"World Health Organization. WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults. WHO (2025) https:\/\/www.who-int.\/WHO guideline on the use of GLP-1 therapies for the treatment of obesity in adults. Accessed 11 Dec 2025"},{"key":"3006_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24360","author":"B Sinha","year":"2025","unstructured":"Sinha B, Ghosal S (2025) Efficacy and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: A Bayesian NMA. Obes (Silver Spring). https:\/\/doi.org\/10.1002\/oby.24360","journal-title":"Obes (Silver Spring)"},{"key":"3006_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100076","author":"HE Bays","year":"2023","unstructured":"Bays HE (2023) Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review. Obes Pillars. https:\/\/doi.org\/10.1016\/j.obpill.2023.100076","journal-title":"Obes Pillars"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03006-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-03006-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03006-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:33:42Z","timestamp":1790757222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-03006-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3006"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-03006-y","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required (analysis of published, anonymized data).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}